1.
|
Phase: Phase IV
Type: Health services research, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: CP005, NCT00385983
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Dathyrca 1, EudrCT 2007-002713-39, HB-2007-043, Data register 2007-41-120, NCT00604318
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: rAd-p53-003, NCT00902122
|
|
4.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00097, 2011-004701-24, NCT01496313
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001K24133E1, NCT01595009
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-2247, NCT00442533
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2009-02-017, NCT01149161
|
|
8.
|
Phase: Phase III, Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DCIC 10 24, NCT01335828
|
|
9.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UCL/10/0299, 2011-000144-21, Cancer Research UK, ISRCTN, NCT01398085
|
|
10.
|
Phase: Phase III
Type: Diagnostic
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: R05-0076, NCT00207298
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Estimabl, CSET 1216, NCT00435851
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2008-09-048, NCT00795782
|
|
13.
|
Phase: Phase III
Type: Diagnostic
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: H10-02695, NCT01373736
|
|
14.
|
Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492
|
|
15.
|
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RC11_0148, NCT01551914
|
|
16.
|
Phase: Phase III
Type: Supportive care
Status: Approved-not yet active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: Hyalobarrier_P3, NCT01696305
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OX4317s, NCT01701349
|
|
18.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 5 to 18
Sponsor: NCI
Protocol IDs: 070189, 07-C-0189, NCI-07-C-0189, NCT00514046
|
|
19.
|
Phase: Phase II, Phase I
Type: Tissue collection/Repository
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 93-102, NCT00579163
|
|
20.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-10-182-B, 10-182-B, 8317, NCT01208051
|
|
21.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 90
Sponsor: NCI
Protocol IDs: 110027, 11-C-0027, NCT01240590
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
|
|
23.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 88498, NCT01471288
|
|
24.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00098, NCT01661179
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000415376, MDA-2004-0059, NCI-6132, 6132, NCT00104871
|
Mobile | Español
